Back to Directory

Iksuda Therapeutics

North East England
Founded 2007
Clinical-stage antibody-drug conjugate developer for cancer

Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat cancers.

Its platform combines stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index.

Clinical programmes include IKS014, a HER2-targeting ADC, and IKS04, a CA242-directed ADC for gastrointestinal cancers.

Iksuda also develops novel payload classes, including protein alkylating agents.

BiotechDrug DiscoveryOncology
BioconjugatesAntibody Therapeutics

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Latest News

Company News2 Aug 2026

Iksuda Therapeutics Wins FDA IND Clearance for IKS04 in GI Cancers

Iksuda Therapeutics has received FDA IND clearance for IKS04, a CA242-directed antibody-drug conjugate, enabling a Phase 1 trial in gastrointestinal cancers including colorectal, gastric, pancreatic and biliary tract tumours. It is the third of Iksuda's ADC programmes to enter the clinic, alongside HER2-directed IKS014, and uses the company's glucuronide-triggered pro-drug technology for tumour-selective payload release.

Source: City AMRead source

Company Notes

Previously Known As
Glythera
Member of